Commonly used clinical doses and adjustments of Daprodustat

Daprodustat (Daprodustat), as a new generation of oral HIF-PHI drug, has attracted attention due to its simple administration method and stable efficacy. During clinical medication, dosage selection and adjustment are crucial. The goal is to improve anemia, reduce blood transfusion dependence, and avoid the risk of excessive elevation of hemoglobin levels. In terms of medication management, daprostat can be taken with food or on an empty stomach. The pharmacokinetic properties are not affected by food, so patients are more flexible in their daily medication. At the same time, it is not significantly interfered by iron or phosphate binders, which facilitates combined medication in patients with chronic kidney disease.

In terms of specific dose selection, for patients who have not received erythropoiesis stimulating agents, if the baseline hemoglobin level is less than9g/dL, the recommended starting dose is 4mg per day; when the hemoglobin level is between 9 and 10g/dL, 2mg per day is usually recommended; if the hemoglobin exceeds 10g/dL, the recommended starting dose is 1mg per day. During treatment, doctors will regularly monitor and adjust the dosage individually based on hemoglobin changes and patient tolerance. It should be emphasized that the maximum recommended dose is 24 mg per day and excessive use is not recommended.

In terms of hemoglobin targets, it is not recommended to target more than 11 g/dL as a treatment goal because too high a level may increase the risk of cardiovascular complications. Therefore, clinical practice places more emphasis on the principle of “lowest effective dose” to maintain hemoglobin in an appropriate range and reduce the need for blood transfusions. Overall, the medication management concept of daplostat focuses on flexibility and safety. Compared with traditional ESA, it is more convenient and provides a new treatment option for patients with anemia in chronic kidney disease. As more clinical data accumulate in the future, dose optimization and long-term efficacy monitoring strategies will be more complete.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat